| Journal | Alcohol and alcoholism (Oxford, Oxfordshire) |
| Study Type | Randomized Trial |
| Population | Human participants |
This study provides important insights into polysubstance use patterns during alcohol treatment, addressing a common clinical scenario where patients present with concurrent substance use. Understanding how cannabis and tobacco use change during alcohol treatment helps clinicians set realistic expectations and develop comprehensive treatment strategies.
This secondary analysis of a 12-week randomized controlled trial examined cigarette and cannabis use patterns in 102 adults receiving treatment for alcohol use disorder with ibudilast. Participants significantly reduced cigarette use throughout the trial period. Cannabis use showed a biphasic pattern—decreasing early in treatment then increasing during the latter phase. Notably, changes in neither cigarette nor cannabis use correlated with the primary alcohol outcome of percent heavy drinking days, though some association was observed with drinks per drinking day.
“I find it clinically reassuring that reductions in cannabis and tobacco use didn’t interfere with alcohol treatment outcomes. This suggests we may not need to tackle all substances simultaneously in early recovery, allowing us to prioritize the most problematic substance first.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- Do patients naturally reduce tobacco and cannabis use when receiving treatment for alcohol use disorder?
- Should clinicians expect that reducing alcohol consumption will automatically lead to reduced tobacco and cannabis use?
- Is it safe to address multiple substance use disorders simultaneously in treatment?
- What should clinicians monitor when treating patients with co-occurring alcohol and cannabis use disorders?
- How common is polysubstance use among patients seeking alcohol treatment?
FAQ
Do patients naturally reduce tobacco and cannabis use when receiving treatment for alcohol use disorder?
Yes, this study found that patients significantly reduced cigarette smoking throughout the 12-week alcohol treatment trial (P = .002). Cannabis use showed a biphasic pattern, decreasing significantly in the early treatment phase (P = .006) before increasing again later in the trial (P = .03).
Should clinicians expect that reducing alcohol consumption will automatically lead to reduced tobacco and cannabis use?
Not necessarily. The study found that changes in cigarette and cannabis use were not significantly associated with the primary alcohol outcome (percent heavy drinking days). This suggests that these substances may need to be addressed independently in treatment planning.
Is it safe to address multiple substance use disorders simultaneously in treatment?
This study provides evidence that concurrent substance use can be addressed during alcohol treatment, as patients naturally reduced cigarette use during the trial. However, cannabis use patterns were more complex, suggesting that individualized treatment approaches may be needed for polysubstance users.
What should clinicians monitor when treating patients with co-occurring alcohol and cannabis use disorders?
Clinicians should monitor cannabis use patterns throughout treatment, as this study showed initial decreases followed by increases during later treatment phases. The biphasic pattern suggests that cannabis use may require specific interventions beyond alcohol-focused treatment.
How common is polysubstance use among patients seeking alcohol treatment?
Alcohol, tobacco, and cannabis are the most frequently used psychoactive substances in the United States and are commonly used concurrently. This study’s findings are particularly relevant given the high prevalence of polysubstance use patterns among individuals with alcohol use disorder.